Cell>Point is a late stage biotech company developing five multi-product platform technologies acquired from The University of Texas M. D. Anderson Cancer. Our lead agent Oncardia®, a theranostic target specific chelation based compound, is being clinically evaluated in a Phase 3 trial study to diagnose the presence and extent of lung cancer, and in a Phase 2b-3 trial study as the first functional “hot spot” imaging agent to specifically target the presence and extent of cardiac ischemia. In cardiac imaging, Oncardia® has the potential to eliminate the need for a stress study which will substantially reduce overall patient time commitment, eliminate the need for the patient to fast before the procedure, and improve both specificity and sensitivity compared to traditional SPECT MPI.
ACC.20/WCC Learning Pathways? (select all that apply) Acute and Stable Ischemic Heart Disease, Congenital Heart Disease, Non Invasive Imaging (Echocardiography/Nuclear/PET/MR and CT)